FibroGen, Inc. — 2021 Form 10-K Summary
Filing identity: The supplied filing identifies the registrant as FibroGen, Inc. (Nasdaq: FGEN), not Kyntra Bio, Inc. It covers the fiscal year ended December 31, 2021 and was filed February 28, 2022.
Business context and reporting period
FibroGen is a biopharmaceutical company developing and commercializing therapies for anemia, fibrosis and cancer. Roxadustat, its oral anemia drug, was approved for CKD anemia in China, Japan and Europe; pamrevlumab remained in late-stage clinical development across several indications. Roxadustat commercialization and development depend significantly on AstraZeneca and Astellas collaboration agreements.
Financial performance and liquidity
| Metric | 2021 | 2020 | Change or context |
|---|---|---|---|
| Revenue | $235.3 million | $176.3 million | Up 33% |
| Operating costs and expenses | $523.8 million | $368.2 million | Up 42% |
| Operating loss | $288.5 million | $191.9 million | Loss widened |
| Net loss | $290.0 million | $189.3 million | Loss widened; 2021 loss per share was $3.14 versus $2.11 |
| Net cash from (used in) operations | $(82.2) million | $81.6 million | Cash generation reversed |
| Cash and cash equivalents | $171.2 million | $678.4 million | Year-end balances |
| Short- and long-term investments | $401.8 million | $8.4 million | Combined with cash: $573.0 million at year-end 2021 |
Revenue comprised $116.4 million license revenue, $70.3 million development and other revenue, $47.6 million net product revenue and $1.0 million drug product revenue. The 2021 increase mainly reflected $120.0 million in Astellas regulatory milestones tied to European approval and an $8.0 million Eluminex license payment. China net product revenue fell 34% to $47.6 million, in part as distribution shifted to the jointly owned Falikang entity and revenue recognition depended on estimated transaction prices and deferred amounts.
R&D expense rose 53% to $387.0 million, including $60.0 million for acquired HiFiBiO in-process R&D and increased pamrevlumab trial and manufacturing costs. SG&A was $123.9 million, up 16%. The filing does not present a gross-margin measure; the company reported an operating loss margin of approximately 123% of revenue and a net loss margin of approximately 123%.
Investing activities used $427.0 million, primarily reflecting purchases of available-for-sale securities and the HiFiBiO payment. Financing activities used $0.6 million. Total liabilities were $544.7 million, including $99.7 million of lease liabilities; the filing reports $17.6 million of Finnish TEKES product-development obligations, with repayment contingent on distributable funds. Contractual lease and purchase obligations totaled $191.0 million, including $73.3 million of purchase obligations. Management said cash, investments and receivables were expected to fund operations for at least 12 months from the report date; approximately $69.9 million of cash was held in China and intended primarily for China operations.
Material changes versus the prior comparable period
- Revenue increased, but the company’s net loss widened by $100.7 million and operating cash flow swung from $81.6 million provided to $82.2 million used.
- Revenue mix shifted: collaboration revenue represented 76% of 2021 revenue and China roxadustat product sales 20%, compared with 59% and 41%, respectively, in 2020.
- The August 2021 FDA complete response letter (CRL) for roxadustat’s U.S. CKD-anemia application led to deferred commercial-supply revenue estimates, uncertainty around U.S. development and commercialization, and a cost-reduction effort.
- FibroGen expanded its preclinical pipeline through HiFiBiO licenses, recording $60.0 million of acquired in-process R&D expense. Its San Francisco headquarters lease was extended through 2028 and reclassified as an operating lease.
Outlook, risks, contingencies and unusual items
- Roxadustat: The FDA said the U.S. application could not be approved in its present form. FibroGen and AstraZeneca discussed a possible additional trial and continued evaluating U.S. development options. Management expected China net sales growth in 2022, with volume gains largely offset by a lower NRDL price effective January 2022.
- Pipeline timing: Management expected MATTERHORN roxadustat MDS data in the second half of 2022 to first half of 2023; ZEPHYRUS-1 IPF and LELANTOS-1 DMD data in the first half of 2023; and LAPIS pancreatic-cancer survival data in the first half of 2024. COVID-19 had delayed or threatened enrollment, especially in IPF, DMD and MDS.
- Financial outlook: The company anticipated continued annual losses and substantial R&D spending. Management cited possible additional financing needs after the stated 12-month runway; equity financing could dilute shareholders, while debt could add covenants and repayment obligations.
- Revenue-estimation uncertainty: The auditor identified determining the transaction price for Falikang sales as a critical audit matter. Management’s estimates included sales volume, performance period, gross transaction price and profit share. The filing also reports $88.8 million of constrained consideration related to drug-product shipments to Astellas and AstraZeneca.
- Legal and regulatory matters: FibroGen and certain current and former officers faced consolidated securities class-action litigation and derivative suits relating to alleged statements about roxadustat trial data and FDA prospects. The SEC subpoenaed the company in Q4 2021 for documents concerning pooled cardiovascular safety data; FibroGen said it was cooperating. Outcomes and potential losses were not estimable.
- China and operations: Risks include price controls, currency and capital-transfer restrictions, changing regulations, reliance on China manufacturing facilities without a secondary source, and cross-border U.S.-China tensions. Although the principal auditor was U.S.-based, the filing says 20%–30% of audit hours were provided by a China-based firm the PCAOB could not inspect.
- Controls: Material weaknesses identified in 2020 involving risk assessment and drug-product revenue controls were reported as remediated by December 31, 2021. Management and the auditor concluded internal control over financial reporting was effective at year-end.
Most important facts for investors to verify
- Confirm the registrant and ticker: the filing is FibroGen, Inc. (FGEN), despite the request metadata naming Kyntra Bio.
- Track FDA feedback, any additional roxadustat trial, and the status of the AstraZeneca U.S./RoW collaboration.
- Assess whether China sales volumes can offset NRDL price reductions and how much cash is accessible outside China.
- Monitor pamrevlumab trial enrollment, readout timing, results and manufacturing transition commitments.
- Review the Falikang revenue-estimation assumptions, deferred revenue and constrained drug-product consideration.
- Follow the securities litigation, SEC investigation and any resulting financial or disclosure effects.
- Compare cash burn and operating plans with management’s stated runway and contractual commitments.